TL;DR
Gene editing is about to stop being a lab procedure and start being a single hospital visit. On March 10, 2027, the FDA is due to decide on lonvo-z, a one-time IV infusion that edits a gene inside the liver to stop the painful swelling attacks of hereditary angioedema. In its Phase 3 trial, one dose cut attacks by 87% against placebo. If it is approved, Intellia says, it would be the world's first CRISPR therapy that edits genes inside the body. Right behind it is a line of one-dose liver editors aimed at cholesterol, kidney-stone disease and copper buildup, which suggests the same recipe can be reused disease after disease. The catch is time: the longest results run months to a year, and a permanent edit has to prove itself over decades.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our Odds board on 5 milestones, starting with "The FDA approves lonvo-z, the first CRISPR therapy that edits genes inside the body by 2027"; our labeled speculation on what it adds up to; and every source.